Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.870 -0.060 (-3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,779,443
Open 1.900
Bid (Size) 1.860 (750)
Ask (Size) 1.900 (2)
Prev. Close 1.930
Today's Range 1.850 - 1.930
52wk Range 1.639 - 12.51
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
IOVA Deadline: Rosen Law Firm Urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire

Performance

YTD
-76.0%
-76.0%
1 Month
-19.0%
-19.0%
3 Month
-45.2%
-45.2%
6 Month
-67.6%
-67.6%
1 Year
-78.6%
-78.6%

More News

Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Via NewMediaWire
Topics Fraud Lawsuit
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Is This Beaten-Down Stock a Millionaire Maker?
Via The Motley Fool
Deadline is July 14, 2025 to Lead in Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox
Via NewMediaWire
Topics Lawsuit
Deadline is July 14, 2025 to Lead in Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Via NewMediaWire
Topics Fraud Lawsuit
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 1.870
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 07/11/25 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 570.82M
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 571M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.